Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-965-8 | CAS number: 112-38-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 5.92 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 25
- Dose descriptor starting point:
- NOAEL
- Value:
- 60 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 148 mg/m³
- Explanation for the modification of the dose descriptor starting point:
1.2 Long-term, inhalation, systemic toxicity
Occupational exposure to undecylenic acid may occur mainly by inhalation of particles or dust. Although it is a solid or a liquid at 21°C with a low vapour pressure, we consider the inhalation route as one of the relevant route for DNEL derivation.
In a 90-day repeated toxicity study performed in rats with undecylenic acid sodium salt (Fabreguettes, 1999), the oral NOAEL for systemic toxicity was 60 mg/kg bw/day.: Cardiomyopathy was recorded at 180 mg/kg bw/d, myocardial degeneration / monocellular aggregation which was reversible during the treatment free period.
Step 1) Relevant dose-descriptor:NOAELrat= 60 mg/kg bw/d
Step 2) Modification of starting point
-Conversion into inhalation NOAEC (in mg/m3) by using an 8-hour respiratory volume for the rat: 0.38 m3/kg bw
- Correction for activity driven differences of respiratory volumes in workers compared to workers in rest: 6.7 m3/10 m3
-Correcting for inhalation to oral absorption: no factor is add.
-100% of absorption is expeted for both oral and inhalation reoute based on absence if data.
The calculation of DNEL is based on the no observed adverse effect level which has to be modified as described in R8 (ECHA, May 2008). For derivation of the inhalative long-term DNEL, the oral NOAEL had to be extrapolated (oral to inhalative) and corrected for interspecies difference between rat and human by the risk assessors: 0.38 mg/m3 (standard respiration volume rat, 8 hours), 6.7 m3 (standard respiration volume human, 8 hours) and 10 m3 (standard respiration volume worker, 8 hours) and 7d/5d (7 days/week of oral exposure during the study, 5 days/week exposure of the workers). An inhalative NOAEC of 60/0.38*6.7/10*7/5 = 148 mg/m3 was obtained.
Step 3) Assessment factors
-Interspecies = 2.5 (data on rat)
-Intraspecies = 5 (workers)
-Exposure duration = 2 (subchronic study)
-Dose response = 1 (dose descriptor = NOAEL)
-Quality of database = 1
Global assessment factor = 25
Step 4) DNEL calculation
DNEL Value (long term inhalation, systemic)= 148 / 25 = 5,92 mg/m3
- AF for dose response relationship:
- 1
- AF for differences in duration of exposure:
- 2
- AF for interspecies differences (allometric scaling):
- 1
- AF for other interspecies differences:
- 2.5
- AF for intraspecies differences:
- 5
- AF for the quality of the whole database:
- 1
- AF for remaining uncertainties:
- 1
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 13.72 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 100
- Dose descriptor starting point:
- NOAEL
- Value:
- 60 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 1 372 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
1.3 Long-term, dermal, systemic toxicity
Occupational exposure to undecylenic acid may also occur by dermal exposure. Although no dermal repeated dose toxicity studies is available as well as no information on dermal absorption, we derived a dermal DNEL based on the same Oral NOAEL selected for the derivation of the inhalation DNEL.
Step 1) Relevant dose-descriptor:NOAELrat= 60 mg/kg bw/d
Step 2) Modification of starting point
Correcting for dermal to oral absorption:
* Correction for absorption difference between rat and human, and between dermal and oral absorption: The results of a recent in vitro dermal absorption study revealed an absorption of 6,12 % though human skin (TNO, 2017). As no available data is reported for oral absorption in rats, the oral absorption is considered to be 100 %: According to REACH guidance, the following caclulation is applied for NOAEL correction:
- Corrected dermal NOAEL, route = oral NOAEL x (ABSoral-rat/ABSderm-rat) x (ABSderm-rat/ ABSderm-human)
-
= oral NOAEL x (ABSoral-rat/ABSderm-human)X 7d/5d
(7 days/week of oral exposure during the study, 5 days/week exposure of the workers)
- Corrected dermal LOAEL = 60 x 100/6,12x7/5 =1372 mg/kg/day
Step 3) Assessment factors
-Interspecies = 2.5 x 4 (data on rat)
-Intraspecies = 5 (workers)
-Exposure duration = 2 (subchronic study)
-Dose response = 1 (dose descriptor = NOAEL)
-Quality of database = 1
Global assessment factor = 100
Step 4) DNEL calculation
DNEL Value (long term dermal, systemic)= 1372 / 100 = 13,72 mg/kg/day
- AF for dose response relationship:
- 1
- AF for differences in duration of exposure:
- 2
- AF for interspecies differences (allometric scaling):
- 4
- AF for other interspecies differences:
- 2.5
- AF for intraspecies differences:
- 5
- AF for the quality of the whole database:
- 1
- AF for remaining uncertainties:
- 1
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- low hazard (no threshold derived)
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- low hazard (no threshold derived)
Additional information - workers
- Corrected dermal NOAEL, route = oral NOAEL x (ABSoral-rat/ABSderm-rat) x (ABSderm-rat/ ABSderm-human)
- = oral NOAEL x (ABSoral-rat/ABSderm-human)
- Corrected dermal LOAEL = 60 x 100/6,12 =980,39 mg/kg/day
1 -Workers
Undecylenic acid can be present as a solid or a liquid, considering the melting point of 21°C. The dustiness is low.
During unloading, unpacking and charging, dermal and/or inhalation contact is possible with:
- solid substance
- airborne dust.
Dermal and/or inhalation contact is possible during breaching of the system with
- liquid substance
- evaporated substance.
That is the reason why we consider the inhalation and dermal route as relevant exposure, and corresponding long term DNEL will therefore be derived
1.1 Short term, inhalation or dermal, local toxicity
Regarding acute toxicity, the DNELacuteonly needs to be derived in case the substance is labelled for an acute toxicity hazard and when peak exposures substantially higher than the DNELlong-termare possible. As both criteria do not apply for undecylenic acid, the derivation of a DNELacuteis not necessary.
Regarding local toxicity, although undecylenic acid is classified irritant to the skin and eyes, no substantially high peak exposure are expected in the plant. Furthermore, the workers are therefore obliged to wear safety goggles, protective work clothes, gloves when handling the substance and respiratory protection if handling high concentrations.
1.3 Long-term, dermal, systemic toxicity
Occupational exposure to undecylenic acid may also occur by dermal exposure. Although no dermal repeated dose toxicity studies is available as well as no information on dermal absorption, we derived a dermal DNEL based on the same Oral NOAEL selected for the derivation of the inhalation DNEL.
Step 1) Relevant dose-descriptor:NOAELrat= 60 mg/kg bw/d
Step 2) Modification of starting point
Correcting for dermal to oral absorption:
* Correction for absorption difference between rat and human, and between dermal and oral absorption: The results of a recent in vitro dermal absorption study revealed an absorption of 6,12 % though human skin (TNO, 2017). As no available data is reported for oral absorption in rats, the oral absorption is considered to be 100 %: According to REACH guidance, the following caclulation is applied for NOAEL correction:
Step 3) Assessment factors
-Interspecies = 2.5 x 4 (data on rat)
-Intraspecies = 5 (workers)
-Exposure duration = 2 (subchronic study)
-Dose response = 1 (dose descriptor = NOAEL)
-Quality of database = 1
Global assessment factor = 100
Step 4) DNEL calculation
DNEL Value (long term dermal, systemic)= 980,39 / 100 = 9,8 mg/kg/day
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1.04 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 50
- Dose descriptor starting point:
- NOAEL
- Value:
- 60 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 52.17 mg/m³
- Explanation for the modification of the dose descriptor starting point:
see below justification
- AF for dose response relationship:
- 1
- AF for differences in duration of exposure:
- 2
- AF for interspecies differences (allometric scaling):
- 2.5
- AF for other interspecies differences:
- 4
- AF for intraspecies differences:
- 5
- AF for the quality of the whole database:
- 1
- AF for remaining uncertainties:
- 1
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 4.9 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 200
- Dose descriptor starting point:
- NOAEL
- Value:
- 60 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 980.39 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
2.2 DNEL long term Dermal, systemic effect
In a 90-day repeated toxicity study performed in rats with undecylenic acid (Fabreguettes, 1999), the oral NOAEL for systemic toxicity was 60 mg/kg bw/day.: Cardiomyopathy was recorded at 180 mg/kg bw/d, myocardial degeneration / monocellular aggregation which was reversible during the treatment free period.
Relevant dose-descriptor:NOAELrat= 60 mg/kg bw/d (Fabreguettes, 1999)
* Correction for absorption difference between rat and human, and between dermal and oral absorption: The results of a recent in vitro dermal absorption study revealed an absorption of 6,12 % though human skin (Maas, 2018). As no available data is reported for oral absorption in rats, the oral absorption is considered to be 100 %: According to REACH guidance, the following caclulation is applied for NOAEL correction:
- Corrected dermal NOAEL, route = oral NOAEL x (ABSoral-rat/ABSderm-rat) x (ABSderm-rat/ ABSderm-human)
- = oral NOAEL x (ABSoral-rat/ABSderm-human)
- Corrected dermal LOAEL = 60 x 100/6,12 =980,39 mg/kg/day
- Assessment factors
- -Interspecies = 2.5 x 4 (data on rat)
- -Intraspecies = 10 (Gen pop)
- -Exposure duration = 2 (subchronic study)
- -Dose response = 1 (dose descriptor = NOAEL)
- -Quality of database = 1
- Global assessment factor = 200
- DNEL calculation: DNEL Value (long term dermal, systemic)= 980,39 / 200 = 4,9 mg/kg/day
- AF for dose response relationship:
- 1
- AF for differences in duration of exposure:
- 2
- AF for interspecies differences (allometric scaling):
- 4
- AF for other interspecies differences:
- 2.5
- AF for intraspecies differences:
- 10
- AF for the quality of the whole database:
- 1
- AF for remaining uncertainties:
- 1
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- low hazard (no threshold derived)
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.3 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 200
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 60 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
2.2 DNEL long term oral, systemic effect
In a 90-day repeated toxicity study performed in rats with undecylenic acid (Fabreguettes, 1999), the oral NOAEL for systemic toxicity was 60 mg/kg bw/day.: Cardiomyopathy was recorded at 180 mg/kg bw/d, myocardial degeneration / monocellular aggregation which was reversible during the treatment free period.
Step 1) Relevant dose-descriptor:NOAELrat= 60 mg/kg bw/d
Step 2) Modification of starting point
No difference in oral absorption is expected between rats and humans. 100% of abosrption is taken for oral absorption
Step 3) Assessment factors
-Interspecies = 2.5 x 4 (data on rat)
-Intraspecies = 10 (general population)
-Exposure duration = 2 (subchronic study)
-Dose response = 1 (dose descriptor = NOAEL)
-Quality of database = 1
Global assessment factor = 200
Step 4) DNEL calculation
DNEL Value (long term dermal, systemic)= 60 / 200 = 0.3 mg/kg/day
- AF for dose response relationship:
- 1
- AF for differences in duration of exposure:
- 2
- AF for interspecies differences (allometric scaling):
- 4
- AF for other interspecies differences:
- 2.5
- AF for intraspecies differences:
- 10
- AF for the quality of the whole database:
- 1
- AF for remaining uncertainties:
- 1
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- low hazard (no threshold derived)
Additional information - General Population
General population
Exposure with undecylenic acid is expected to be low as it is used as an intermediate. Undecylenic acidis an organic unsaturated fatty acid derived from natural castor oil.It is used as an intermediate in the manufacturing of food aroma and in the manufacture of musk fragrances for perfumes.Undecylenic acid is a natural fungicide and is used as an intermediate in the manufacturing of anti fungus products for pharmaceutical and cosmetic use. It is further used as an intermediate in the synthesis of fine chemicals and the manufacture of polymers of salts for anti-corrosive additives and of products that enter the formulation of anti-dandruff shampoo.
If there is exposure, it will be minor and mainly occur via dermal and oral route.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.